Kyverna Therapeutics, INC

Kyverna Therapeutics and ElevateBio have entered into a Clinical and Commercial Supply Agreement to secure manufacturing for Kyverna's lead cell therapy candidate, miv-cel.

Kyverna Therapeutics has amended its loan and security agreement with Oxford Finance LLC, extending loan availability and modifying milestone-based draw conditions.

Kyverna Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of two Class II directors and the ratification of its independent auditor.

Kyverna Therapeutics announced the appointment of Gregory Martini as its new Chief Financial Officer, effective May 18, 2026, succeeding Marc Grasso.

Kyverna Therapeutics announces the appointment of Nadia Dac as Chief Commercial Officer, effective May 4, 2026, to lead commercial strategy for miv-cel.

Kyverna Therapeutics announced positive longer-term follow-up data from its Phase 2 trial of miv-cel in generalized myasthenia gravis and primary analysis results from its registrational trial in stiff person syndrome.

Kyverna Therapeutics reported a decrease in R&D expenses for Q1 2026, alongside progress in its clinical trials for autoimmune diseases.

Kyverna Therapeutics reports increased net losses for Q3 and nine months ended September 30, 2025, while advancing its lead cell therapy candidate KYV-101 in late-stage clinical trials for autoimmune diseases and securing new financing.

Kyverna Therapeutics reported increased net losses in Q2 2025 driven by higher R&D expenses, while making significant clinical progress with its lead cell therapy candidate KYV-101 for autoimmune diseases.

Kyverna Therapeutics reports a net loss of $44.6 million for Q1 2025, focusing on advancing its lead product candidate, KYV-101, through clinical trials.

Kyverna Therapeutics, a clinical-stage biopharmaceutical company, announced its third quarter 2024 financial results, highlighting increased operating expenses due to ongoing clinical trials and research and development activities.

Kyverna Therapeutics reports a net loss of $28.8 million for the second quarter of 2024, alongside significant increases in research and development expenses.

Kyverna Therapeutics' 10-K filing summarizes the company's focus on developing cell therapies for autoimmune diseases, highlighting clinical trial progress and financial results for 2024.

Kyverna Therapeutics' 10-K filing details its capital stock, governance structure, and key agreements, highlighting its focus on cell therapies for autoimmune diseases.

Director Ian T. Clark acquired 5,093 restricted stock units and 20,582 stock options in Kyverna Therapeutics, Inc.

Director Fred E. Cohen acquired 5,093 restricted stock units and 20,582 stock options in Kyverna Therapeutics, Inc.

Director Beth Seidenberg acquired 5,093 restricted stock units and 20,582 stock options in Kyverna Therapeutics.

Executive Chairperson Christi Shaw disposed of 4,194 shares of Kyverna Therapeutics common stock to satisfy tax obligations.

Director Mert Aktar acquired 5,093 restricted stock units and 20,582 stock options in Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc. reports that Chief Financial Officer Gregory S. Martini was granted stock options on May 18, 2026.

Kyverna Therapeutics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for May 27, 2026, detailing proposals for director elections and auditor ratification.

Kyverna Therapeutics announces its 2025 Annual Meeting of Stockholders, detailing proposals for director elections and auditor ratification.

Kyverna Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on May 29, 2025, featuring proposals for director elections and auditor ratification.

Kyverna Therapeutics, a clinical-stage biopharmaceutical company focused on autoimmune diseases, is planning an initial public offering to raise approximately $272.6 million for clinical development and research.

Kyverna Therapeutics is seeking to raise approximately $182.3 million through an initial public offering to further the clinical development of its cell therapies for autoimmune diseases.

Kyverna Therapeutics, a clinical-stage biopharmaceutical company, has filed for an initial public offering to further develop its cell therapies for autoimmune diseases, including its lead candidate KYV-101.

Westlake BioPartners entities and Dr. Beth C. Seidenberg filed an amended Schedule 13G for Kyverna Therapeutics, Inc., reporting a combined 7.8% beneficial ownership.

GordonMD Global Investments and related entities report a 7.0% beneficial ownership stake in Kyverna Therapeutics, Inc. common stock.